Search Results 991-1000 of 18568 for Relapse
The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...
This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal ...
This study aims to determine if any of three new GVHD prophylaxis approaches improves the rate of GVHD and relapse free survival at one year after ...
NL-201 in Patients With Relapsed or Refractory Cancer. Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to ...
Root Cause of Multiple Myeloma Relapse Revealed. Dana Sparks. September 18, 2013. Mayo Clinic Receives $8.8 Million Federal Grant for Metabolomics Center.
... relapse. The study has demonstrated that digital phenotyping can detect meaningful signals correlating with relapse predictors, supporting its ...
... relapse within the first 6 months following study drug discontinuation will have the option of receiving open-label abatacept for a maximum of 12 months.
Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma featured. Cancer. Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.